SCHEMBL2023904

SCHEMBL2023904

CN=CCC1CCCOC1

nearest known ligand 0.33

Predicted protein targets (top 3)

geneUniProtsupporting neighboursconfidence
PDE8B O95263 1/20 0.33
BRD4 O60885 3/20 0.30
NOS2 P35228 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2025052 1.00 PDE8B (0.33) PDE8BBRD4NOS2
SCHEMBL2023900 1.00 PDE8B (0.33) PDE8BBRD4NOS2
SCHEMBL2025053 1.00 PDE8B (0.33) PDE8BBRD4NOS2
SCHEMBL2023906 1.00 PDE8B (0.33) PDE8BBRD4NOS2
SCHEMBL2023903 1.00 PDE8B (0.33) PDE8BBRD4NOS2
SCHEMBL1567543 0.75
SCHEMBL2023890 0.75
SCHEMBL2022535 0.75
SCHEMBL2023891 0.75
SCHEMBL2028005 0.75

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8580823-B2 Piperidine renin inhibitors VITAE PHARMACEUTICALS, INC. (US) 2013-11-12 US disclosed
EP-2074108-B3 RENIN INHIBITORS VITAE PHARMACEUTICALS INC (US) 2013-06-26 EP disclosed
EP-2581366-A1 Renin Inhibitors Vitae Pharmaceuticals, Inc. (US) 2013-04-17 EP disclosed
EP-2074108-B1 RENIN INHIBITORS VITAE PHARMACEUTICALS INC (US) 2012-11-21 EP disclosed
US-20120225906-A1 PIPERIDINE RENIN INHIBITORS VITAE PHARMACEUTICALS, INC. 2012-09-06 US disclosed
US-8198453-B2 Piperidine renin inhibitors VITAE PHARMACEUTICALS, INC. (US) 2012-06-12 US disclosed
US-20110160300-A1 Renin Inhibitors and Methods of Use Thereof VITAE PHARMACEUTICALS, INC. 2011-06-30 US disclosed
US-20100311989-A1 PROCESS FOR THE PREPARATION OF RENIN INHIBITORS VITAE PHARMACEUTICALS, INC. 2010-12-09 US disclosed
US-20100160424-A1 RENIN INHIBITORS VITAE PHARMACEUTICALS, INC. 2010-06-24 US disclosed
US-20090312369-A1 Renin Inhibitors VITAE PHARMACEUTICALS , INC. 2009-12-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120225906-A1 PIPERIDINE RENIN INHIBITORS ACE, PEPD, DNPEP PDE8B 2156/4885BRD4 1079/4885NOS2 2576/4885
US-20100160424-A1 RENIN INHIBITORS ACE, REN, DNPEP PDE8B 1224/4885BRD4 1213/4885NOS2 4071/4885
US-20110160300-A1 Renin Inhibitors and Methods of Use Thereof REN, ACE, AGTR1 PDE8B 513/4885BRD4 2107/4885NOS2 2541/4885
US-20100311989-A1 PROCESS FOR THE PREPARATION OF RENIN INHIBITORS REN, ACE, AGTR1 PDE8B 748/4885BRD4 1832/4885NOS2 1023/4885
US-20090312369-A1 Renin Inhibitors ACE, REN, DNPEP PDE8B 1687/4885BRD4 2248/4885NOS2 3295/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.